Pharvaris (PHVS) Expected to Announce Quarterly Earnings on Wednesday

Pharvaris (NASDAQ:PHVS) is expected to be announcing its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect Pharvaris to post earnings of ($0.80) per share for the quarter. Interested persons can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, November 19, 2025 at 4:00 PM ET.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Tuesday, August 12th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.07). On average, analysts expect Pharvaris to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Pharvaris Stock Down 1.0%

PHVS opened at $21.59 on Monday. The firm has a market cap of $1.13 billion, a PE ratio of -6.43 and a beta of -2.78. The business has a fifty day simple moving average of $23.01 and a 200-day simple moving average of $20.45. Pharvaris has a fifty-two week low of $11.51 and a fifty-two week high of $26.33.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on PHVS shares. JMP Securities dropped their price target on Pharvaris from $55.00 to $52.00 and set a “market outperform” rating on the stock in a research note on Wednesday, August 13th. Bank of America upgraded shares of Pharvaris from an “underperform” rating to a “neutral” rating and raised their target price for the stock from $16.00 to $27.00 in a report on Thursday, October 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a report on Wednesday, October 8th. HC Wainwright assumed coverage on shares of Pharvaris in a research report on Wednesday, October 15th. They issued a “buy” rating and a $60.00 price target for the company. Finally, Zacks Research upgraded shares of Pharvaris from a “strong sell” rating to a “hold” rating in a research report on Monday, August 18th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.17.

Hedge Funds Weigh In On Pharvaris

Several institutional investors and hedge funds have recently modified their holdings of PHVS. Geode Capital Management LLC grew its holdings in Pharvaris by 41.1% during the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock valued at $952,000 after purchasing an additional 15,769 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after buying an additional 783 shares during the period. Legal & General Group Plc boosted its holdings in shares of Pharvaris by 17.2% during the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after buying an additional 1,695 shares during the period. Amundi grew its stake in Pharvaris by 2,741,600.0% in the 2nd quarter. Amundi now owns 27,417 shares of the company’s stock valued at $489,000 after buying an additional 27,416 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in Pharvaris by 19.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock worth $860,000 after acquiring an additional 7,879 shares during the period.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.